Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin - Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million  - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02...